Previous 10 | Next 10 |
Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.65 (-27.5% Y/Y) and the consensus Revenue Estimate is $5.16M (+2935.3% Y/Y). Over the last 3 months, EPS estimates have seen 4 upw...
ADT,AGEN,AGTC,ALLT,APRN,AUD,OTCPK:BAYZF,BHVN,BNTX,BSY,CAH,CANO,CCO,CEVA,CNCE,CORR,DCTH,DHI,DRNA,EBIX,ECOM,EGRX,EPZM,EXK,FOLD,GILT,GLNG,GOL,HAE,HAIN,HGV,HUYA,IGT,IIVI,INSW,ISEE,ITCI,KNDI,KPLT,MIDD,MLCO,MNTV,MRNS,MRSN,MSGE,OTCPK:NSANY,NSPR,NUWE,OCGN,OESX,OSG,OWL,PLTR,PRPL,PRTY,QTNT,SATS,SEAS,SE...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial results for the third quarter ended September 30, 2021 before the market opens o...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has joined forces with the Loulou Foundation , a private foundation dedicated to advancing research on t...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will be presenting an overview and update of its pipeline and commercial plans across its programs in CDKL5 deficiency disorder...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host a virtual R&D event for investors and analysts on Tuesday, October 5, 2021, from 9:00 a.m. to 12:00 p.m. Eastern ...
Six-month priority review granted with PDUFA target action date set for March 20, 2022 FDA indicated that it is not currently planning to hold an advisory committee meeting for the application NDA filing acceptance enables opportunity to draw $...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has grant...
Primary endpoint showed a median 16.6% reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23) Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results...
Burry buys puts on ARKK, possibly as a hedge to Alphabet and Facebook positions. He also took a position in Discovery, which is merging with AT&T's entertainment assets and will collapse its multiple share class structure when the deal closes. Michael Burry takes his first rep...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...